Author: Roberto Bernardi

I am a dynamic author specialising in articles about technology, construction, and property. Originally from Italy, I blend my European perspective with a forward-thinking approach to deliver insightful and practical content.
  • The Tokenisation of Everything: How Blockchain Is Quietly Revolutionising Asset Ownership in 2026

    The Tokenisation of Everything: How Blockchain Is Quietly Revolutionising Asset Ownership in 2026

    There is a moment in financial history when the infrastructure shifts so fundamentally that the old gatekeepers simply become irrelevant. The invention of the joint-stock company did it in the seventeenth century. The London Stock Exchange did it in 1801. And now, quietly but with considerable force, real world asset tokenisation in 2026 is doing it again, dissolving the walls between institutional capital and everyone else, one digital token at a time.

    This is not a story about cryptocurrency speculation or NFT fever. Those episodes, colourful as they were, were largely rehearsals. What is happening now is structurally different: established asset classes, prime property in Edinburgh’s New Town, a Damien Hirst sculpture, a stake in a mid-market private equity fund, are being converted into digital tokens on regulated blockchains, traded with legal clarity, and made accessible to investors who would previously have been turned away at the door.

    Financial professionals discussing real world asset tokenisation 2026 in a London office with digital displays
    Financial professionals discussing real world asset tokenisation 2026 in a London office with digital displays

    What Real World Asset Tokenisation Actually Means

    Strip away the technical language and the concept is straightforward. A real world asset, something with tangible value that exists off a blockchain, is represented as a digital token. Ownership of that token confers a legally enforceable claim on the underlying asset, or a proportional share of its income and appreciation. The blockchain provides the ledger: immutable, transparent, and accessible without a clearing house or a custody bank extracting fees at every juncture.

    The tokenisation can be fractional. A Georgian townhouse in Bath worth £2.4 million might be divided into 24,000 tokens at £100 each. A pension-age investor in Dundee who cannot commit £500,000 to a property fund minimum can now hold a meaningful, liquid position in prime residential real estate. A collector who loves Basquiat but cannot afford the whole canvas can own a verified fraction of it. These are not hypotheticals. Platforms are executing these structures today, increasingly under the scrutiny, and, critically, the regulatory frameworks, of the Financial Conduct Authority.

    Why 2026 Is the Inflection Point

    The FCA’s sandbox approach to tokenised securities, combined with the UK Government’s stated ambition to position Britain as a global hub for digital assets, has created genuine institutional momentum. HM Treasury published its digital assets regulatory framework to considerable attention, and whilst implementation has been incremental, it has sent the signal that matters most to institutional capital: this is legal, this is supervised, and this is here to stay.

    Globally, research from the Boston Consulting Group estimated that tokenised assets could represent $16 trillion in value by 2030. Within the UK, real world asset tokenisation in 2026 is attracting serious attention from pension funds, family offices, and wealth managers who previously dismissed blockchain as a retail curiosity. The difference now is settlement speed, regulatory clarity, and the emergence of institutional-grade custody solutions.

    The Asset Classes Being Transformed

    Property

    UK residential and commercial property has long been the most coveted asset class and the most inaccessible. Tokenisation is chipping at both problems simultaneously. Fractional ownership structures are allowing retail investors entry at four-figure sums whilst providing developers with an alternative fundraising channel that bypasses traditional bank lending. The secondary market liquidity, being able to sell your token position without waiting for an entire property transaction to complete, is arguably the single most transformative feature. Anyone who has sold a house in England will appreciate precisely why that matters.

    Fine Art and Collectibles

    The art market has historically rewarded the well-connected above all else. Auction houses set the terms, private dealers hold the relationships, and provenance disputes have derailed many an acquisition. Tokenised art, recorded on an immutable ledger, addresses the provenance question with unusual elegance. Several platforms are now working directly with London galleries and estate representatives to tokenise works, with the blockchain record serving as both ownership certificate and exhibition history.

    Tablet showing tokenised property investment platform, illustrating real world asset tokenisation 2026
    Tablet showing tokenised property investment platform, illustrating real world asset tokenisation 2026

    Private Equity and Credit

    This is perhaps where the disruption cuts deepest. Private equity funds have traditionally required minimum commitments of £250,000 or more, locking investors in for seven to ten years with minimal liquidity. Tokenised private equity structures are beginning to offer quarterly liquidity windows, lower entry thresholds, and automated distribution of carried interest through smart contracts. The fund administrator, the transfer agent, the custodian: each one sees their margin threatened. The institutional reaction has been predictable, several have moved to acquire tokenisation platforms rather than resist them.

    Infrastructure and Commodities

    Renewable energy projects, port infrastructure, and even agricultural land are entering tokenisation pipelines. A solar farm in Lincolnshire raising expansion capital via tokenised revenue-sharing agreements is a genuinely novel structure that offers retail investors inflation-linked returns tied to actual kilowatt-hour output. It is complex, it requires careful legal architecture, and it is happening.

    The Risks That Sophisticated Investors Must Understand

    A genuinely clear-eyed assessment cannot ignore the considerable risks. Liquidity is promised but not guaranteed; secondary markets for tokenised assets remain thin outside the largest platforms, and a token is only as liquid as the buyers willing to purchase it. Smart contract vulnerabilities have cost investors hundreds of millions globally. Jurisdictional ambiguity persists: a token representing a Scottish property, held on a Swiss blockchain, traded by an investor in Singapore, raises questions that no single regulator has yet definitively answered.

    Valuation remains deeply imperfect. The underlying asset, whether a Mayfair flat or a Warhol print, requires independent appraisal, and those appraisals carry the same subjectivity they always have. Tokenisation does not transform a poorly valued asset into a well-valued one; it merely distributes that valuation risk more broadly.

    The FCA has been explicit that tokenised securities which meet the definition of regulated investments fall under existing financial promotion rules. Any platform that sidesteps this by claiming their tokens are something other than securities warrants substantial scepticism.

    What This Means for Traditional Financial Intermediaries

    The longer-term consequence for wealth managers, private banks, and fund administrators is significant but not immediately catastrophic. The most astute incumbents are incorporating tokenisation into their own offerings. Several UK wealth management firms have begun offering tokenised exposure to alternative assets as a complement to conventional portfolios, recognising that the client demand is real and that resistance is commercially self-defeating.

    The intermediaries most at risk are those whose value proposition rests entirely on exclusive access rather than genuine expertise. If a family office’s primary function is providing entry to a fund that is now tokenised and broadly accessible, the justification for its fee structure becomes rather thin. Expertise, judgement, and personalised counsel retain their value. Administrative gatekeeping, considerably less so.

    How to Approach This as an Investor in 2026

    The appropriate posture is one of engaged curiosity rather than wholesale commitment. Real world asset tokenisation in 2026 is a maturing market, not a mature one. Due diligence must cover the legal wrapper, the regulatory status of the platform, the quality of the underlying asset, the custody arrangement for the tokens, and the realistic liquidity conditions. These are not easy questions, and any platform that makes them sound easy deserves additional scrutiny.

    For those prepared to do that work, the opportunity is genuine. Access to assets that were structurally closed to all but the wealthiest institutions is not a trivial development. It is, potentially, one of the more consequential shifts in the architecture of private wealth this generation will witness.

    Frequently Asked Questions

    What is real world asset tokenisation and how does it work?

    Real world asset tokenisation converts ownership rights in tangible assets, property, art, private equity, into digital tokens on a blockchain. Each token represents a legally enforceable fractional claim on the underlying asset, enabling purchase, sale, and transfer without traditional intermediaries like custodian banks or clearing houses.

    Is real world asset tokenisation legal in the UK?

    Yes, provided the structure complies with FCA regulations. Tokenised securities that meet the definition of regulated investments fall under existing UK financial services law, including financial promotion rules. HM Treasury has published a digital assets regulatory framework to provide greater clarity, and FCA-regulated platforms must adhere to standard authorisation requirements.

    What is the minimum investment for tokenised assets in the UK?

    Minimum investment thresholds vary by platform and asset class, but fractional tokenisation is specifically designed to lower entry points dramatically. Some property tokenisation platforms accept investments from as little as £100 to £500, compared to the £250,000-plus minimums typical of institutional private equity funds.

    How liquid are tokenised assets compared to traditional investments?

    Liquidity is one of tokenisation’s key promises but also one of its current limitations. Secondary markets exist but remain relatively thin for most tokenised assets outside the largest platforms. Investors should treat liquidity as a potential rather than a guarantee, and examine platform-specific secondary market conditions carefully before committing capital.

    What are the main risks of investing in tokenised real world assets?

    Key risks include smart contract vulnerabilities, thin secondary market liquidity, valuation uncertainty in the underlying asset, jurisdictional regulatory ambiguity, and platform counterparty risk. The FCA does not guarantee the performance of any tokenised investment, and investors should conduct thorough due diligence on both the platform’s regulatory status and the quality of the underlying asset.

  • Climate Anxiety Is Now a Public Health Crisis, Here’s What Governments Are Finally Doing About It

    Climate Anxiety Is Now a Public Health Crisis, Here’s What Governments Are Finally Doing About It

    For years, ecologists and psychologists occupied separate disciplines, rarely speaking the same language. That division is dissolving fast. A mounting body of peer-reviewed research now places climate anxiety squarely within the public health canon, no longer a fringe concern for coastal ecologists or catastrophising teenagers, but a measurable, diagnosable pressure affecting populations across every continent. Governments are beginning to take it seriously. Some are even legislating around it.

    What has changed is the quality of the evidence. The Lancet Countdown on Health and Climate Change, which publishes annually and carries considerable weight with policymakers, documented in its most recent report that extreme heat events, flooding, and prolonged wildfire seasons are generating cascading psychological consequences: elevated rates of depression, post-traumatic stress, grief, and what researchers term “solastalgia”, the distress caused by environmental change in one’s own home environment. These are not metaphors. They are clinical presentations arriving in GP surgeries and mental health clinics with increasing frequency.

    Young woman on a rain-soaked park bench reflecting on climate anxiety public health concerns in a British urban setting
    Young woman on a rain-soaked park bench reflecting on climate anxiety public health concerns in a British urban setting

    What Does Climate Anxiety Actually Look Like in Practice?

    The term “climate anxiety” risks sounding vague, even self-indulgent, to those unfamiliar with the clinical literature. It is neither. The American Psychological Association first formalised the concept in 2017, but UK researchers have since developed their own frameworks. A 2021 study by the University of Bath surveyed 10,000 young people across ten countries and found that 59 per cent felt very or extremely worried about climate change. Among UK respondents, 40 per cent said climate feelings affected their daily functioning. That is not background noise. That is a public health signal.

    Clinicians distinguish between adaptive anxiety, which motivates action, and maladaptive anxiety, which paralyses. The latter manifests as sleep disturbance, intrusive thoughts, avoidance of news, strained relationships, and in more acute cases, a reluctance to have children. Younger cohorts are disproportionately affected, but the NHS is also seeing older patients presenting with grief responses following flooding events, particularly in communities such as those in the Somerset Levels and parts of Yorkshire that have experienced repeated inundation.

    The UK’s Policy Response: Cautious Progress

    Britain’s approach to climate anxiety as a public health matter remains, to be charitable, in its early stages. The NHS Long Term Plan acknowledged environmental determinants of health in broad terms, but specific commissioning around climate-related psychological distress has been patchy at best. What has emerged instead are localised initiatives and pilot programmes, several of them genuinely thoughtful.

    NHS England has begun integrating climate health literacy into social prescribing frameworks, meaning GPs can now refer patients to “green social prescribing” projects. These schemes, trialled across seven sites including South Yorkshire and Humberside, connect patients with outdoor activities, conservation volunteering, and community gardening. Early results, published by NHS England in 2025, showed statistically significant improvements in wellbeing scores among participants. The logic is elegant: reconnecting people to the natural world addresses both the disconnection that fuels ecological grief and the sedentary isolation that worsens generalised anxiety.

    The UK Health Security Agency has also published guidance acknowledging that extreme weather events carry mental health consequences that must be planned for alongside physical ones. Flood recovery packages in several local authority areas now include mandatory mental health signposting, something that would have been considered an afterthought five years ago.

    NHS GP consultation desk with mental health leaflet related to climate anxiety public health resources
    NHS GP consultation desk with mental health leaflet related to climate anxiety public health resources

    How the EU Is Moving Further and Faster

    Where the UK has moved cautiously, the European Union has shown considerably greater structural ambition. The EU Mission on Cancer has been complemented by growing political interest in what some Brussels officials are calling a “climate health mission”, a cross-portfolio initiative linking environmental policy directly to mental health outcomes.

    Finland, consistently ranked among the world’s happiest countries, has integrated climate mental health education into its national school curriculum. Pupils are taught not only about ecological systems but about processing difficult emotions related to environmental change, a form of climate psychology that Finnish researchers argue reduces maladaptive anxiety whilst building civic resilience. Germany has established dedicated climate psychology clinics within several university hospital networks, and early demand has significantly exceeded initial projections.

    The World Health Organisation designated climate change as the defining public health threat of the 21st century, and its regional office for Europe has since published a technical guidance document on mental health and climate change, urging member states to embed psychological support within their national adaptation plans. For those interested in the full scope of WHO’s position, their European climate and health framework is worth examining.

    The Generational Fault Line

    No serious discussion of climate anxiety as a public health challenge can sidestep the generational dimension. Young people in the UK, broadly those born after 1997, have grown up with climate change as a fixed feature of their consciousness rather than a distant scientific abstraction. The psychological literature is beginning to reflect what youth mental health workers have known anecdotally for years: that this cohort experiences a particular form of anticipatory grief, mourning a future they feel has already been foreclosed.

    Organisations such as Young Minds and the Climate Psychology Alliance in the UK are lobbying for climate-aware therapy training as a standard component of counsellor and psychotherapist accreditation. At present, most practising therapists receive no formal education on how to work with climate-related distress, which means patients raising these concerns frequently encounter well-meaning but underprepared clinicians who attempt to reframe ecological anxiety as a cognitive distortion to be corrected. The Climate Psychology Alliance argues, persuasively, that this fundamentally misunderstands the problem: the anxiety is, in large part, a rational response to a real threat.

    From Awareness to Infrastructure: What Good Policy Looks Like

    The emerging consensus among researchers and policymakers who take climate anxiety public health seriously points toward a three-tier response. First, population-level awareness and destigmatisation: naming climate grief as a legitimate psychological experience removes the shame that prevents people from seeking support. Second, clinical capacity: training mental health professionals in climate-aware therapeutic approaches, funding specialised services, and ensuring that GP practices in high-risk areas have clear referral pathways. Third, structural intervention: because the most effective treatment for climate anxiety is ultimately reducing climate change itself, mental health and environmental policy cannot remain siloed.

    Scotland’s approach, under its National Performance Framework, is perhaps the most integrated in the UK, explicitly linking wellbeing outcomes to environmental sustainability indicators. It is imperfect, and implementation varies considerably by health board, but the framework at least acknowledges what the evidence demands: that a healthy population and a healthy planet are not separate policy objectives.

    The Road Ahead

    Climate anxiety is not going away. The physical realities driving it are accelerating, and the psychological literature tracking its effects is growing sharper and more alarming with each successive report. The question governments face is not whether this constitutes a public health issue; that case has been made and largely accepted. The question is whether the institutional response will match the scale of the problem before the window for genuinely preventive action closes.

    There is, paradoxically, something mildly reassuring in the fact that policymakers are finally asking the question. The NHS green social prescribing pilots, the EU’s cross-portfolio health missions, Finland’s classroom curricula, and the WHO’s regional guidance all represent serious institutional acknowledgement that the psychological cost of environmental breakdown is real, measurable, and deserving of a proper response. That is not enough. But it is, at least, a beginning.

    Frequently Asked Questions

    What is climate anxiety and is it a recognised mental health condition?

    Climate anxiety refers to persistent worry, distress, or fear related to climate change and its consequences. Whilst not a standalone diagnostic category in the ICD-11, it is increasingly recognised by clinical bodies including the NHS and the Climate Psychology Alliance as a significant psychological experience that can impair daily functioning and require professional support.

    How widespread is climate anxiety in the UK?

    Research from the University of Bath found that a significant proportion of UK young people report climate concerns affecting their daily lives. NHS mental health services have noted rising presentations linked to flooding events and broader ecological distress, particularly among under-35s and communities in flood-prone regions such as Yorkshire and the Somerset Levels.

    What is the NHS doing about climate-related mental health issues?

    The NHS has integrated climate health considerations into its green social prescribing framework, connecting patients experiencing anxiety or low mood with outdoor and conservation-based activities. Early pilot data from seven NHS sites, published in 2025, showed measurable improvements in participant wellbeing scores. Dedicated clinical pathways for climate-related distress remain limited but are under development.

    How are other countries tackling climate anxiety as a public health problem?

    Finland has embedded climate psychology into its national school curriculum, helping young people process ecological emotions as part of standard education. Germany has opened dedicated climate psychology clinics within university hospitals, whilst the EU is developing cross-portfolio health missions linking environmental and mental health policy. The WHO’s European regional office has also published technical guidance urging member states to include psychological support in national adaptation plans.

    Is climate anxiety the same as eco-grief or solastalgia?

    These terms are related but distinct. Eco-grief refers specifically to mourning environmental losses, such as species extinction or landscape destruction. Solastalgia describes distress caused by changes to one’s immediate home environment, often following flooding or habitat destruction. Climate anxiety is broader, encompassing anticipatory fear about future environmental deterioration. All three can co-exist and may benefit from climate-aware therapeutic approaches.

  • Longevity Science Is No Longer for the Elite: The Mainstream Wellness Treatments Backed by New Research

    Longevity Science Is No Longer for the Elite: The Mainstream Wellness Treatments Backed by New Research

    For years, the science of living longer and healthier was the exclusive preserve of Californian tech billionaires with private physicians and seven-figure health budgets. Bryan Johnson making headlines by transfusing his son’s blood plasma. Peter Thiel reportedly banking on parabiosis. The whole enterprise had an air of the baroque, even the desperate. But something has shifted, and it has shifted quickly. The longevity treatments 2026 are increasingly grounded in rigorous clinical evidence, increasingly available through UK private clinics, and increasingly affordable for anyone who takes their health with reasonable seriousness. This is not wellness fluff. It is a genuine pharmaceutical and diagnostic revolution.

    A woman reviewing longevity treatments 2026 data with her physician in a London private clinic
    A woman reviewing longevity treatments 2026 data with her physician in a London private clinic

    What Are Senolytics and Why Should You Care?

    The most significant clinical development in ageing science over the past decade is the emergence of senolytics: compounds that selectively clear senescent cells from the body. Senescent cells are, in the bluntest terms, cells that have stopped dividing but refuse to die. They accumulate with age and secrete a cocktail of inflammatory proteins that damage surrounding tissue, driving conditions from arthritis to cardiovascular disease to cognitive decline.

    The leading senolytic combination studied in human trials is dasatinib and quercetin. Dasatinib is a leukaemia drug; quercetin is a plant flavonoid found in onions and capers. Together, they have shown promising results in trials at the Mayo Clinic and, more recently, at University College London, where researchers observed measurable reductions in senescent cell burden in older patients with idiopathic pulmonary fibrosis. The regime is typically administered in short, intermittent bursts rather than daily dosing, which reduces side-effect risk considerably.

    In the UK, quercetin supplements are freely available from brands such as Viridian and Solgar. Dasatinib, being a prescription drug regulated by the MHRA, requires clinical oversight. A growing number of London-based longevity clinics, including Harpal Clinic and the Hooke Longevity Clinic in Marylebone, now offer senolytic protocols under medical supervision, typically priced between £800 and £2,500 for an initial programme including bloodwork and follow-up. That is not trivial, but it is a far cry from the seven-figure territory of five years ago.

    Continuous Glucose Monitoring: The Most Democratised Longevity Tool of the Era

    Perhaps no single longevity technology has crossed from elite experimentation into mainstream use as decisively as continuous glucose monitoring, or CGM. Originally designed for diabetics, the small sensor worn on the upper arm now appears on the bodies of triathletes, hedge fund managers and, increasingly, people who simply want to understand how their diet affects their metabolic health in real time.

    The clinical rationale is compelling. Chronic glycaemic variability, even in people who test as non-diabetic on standard fasting glucose tests, is associated with accelerated biological ageing, cognitive impairment and elevated cardiovascular risk. A CGM device reveals exactly how your body responds to white rice versus brown, a croissant versus porridge, alcohol versus sleep deprivation. The feedback loop is immediate and, for most users, genuinely revelatory.

    In the UK, Abbott’s Libre Sense and the Dexterity platform have made CGM accessible without a prescription for non-diabetic users through services such as Zoe, the gut microbiome and metabolic health company co-founded by Professor Tim Spector of King’s College London. Zoe’s programme, which costs approximately £299 for the initial testing phase, combines CGM data with microbiome analysis and personalised dietary recommendations. The NHS uses CGM extensively for Type 1 diabetes management, and there is growing advocacy for wider metabolic screening, particularly following ONS data showing that an estimated 3.8 million people in England are living with pre-diabetes, many undiagnosed.

    Continuous glucose monitoring sensor worn on the arm, a key longevity treatment in 2026
    Continuous glucose monitoring sensor worn on the arm, a key longevity treatment in 2026

    NAD+ Precursors: The Supplement With the Most Clinical Weight

    Nicotinamide adenine dinucleotide, NAD+, is a coenzyme present in every cell in the body and central to energy metabolism and DNA repair. Its levels decline steeply with age. Supplementing with NAD+ precursors, principally nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), has become one of the most studied areas in longevity science, with human trials now published in peer-reviewed journals including Nature Ageing and Cell Metabolism.

    The results are not uniformly dramatic. Some studies show improved muscle function, cognitive clarity and reduced markers of inflammation in older adults. Others show more modest effects. What is clear is that NR and NMN are generally well tolerated and that their mechanism of action is biologically plausible in a way that many wellness supplements simply are not. Elysium Health’s Basis, containing NR and pterostilbene, has amassed more human trial data than almost any other longevity supplement on the market. In the UK, NMN supplements are available from Renue By Science and Double Wood Supplements, typically at £40 to £90 per month, putting them firmly within mainstream reach.

    Rapamycin: The Most Discussed Drug You Have Probably Never Heard Of

    Rapamycin is an immunosuppressant typically used to prevent organ transplant rejection. It is also the most consistently life-extending compound ever tested in animal models, including mice, where it extended median lifespan by up to 25 per cent even when administered late in life. It works by inhibiting mTOR, a signalling pathway that governs cell growth and metabolism, effectively nudging cells into a more cautious, repair-oriented mode.

    Human data is still limited but accumulating. The PEARL trial and ongoing work at the Karolinska Institute in Stockholm are among the more rigorous human studies. In the UK, off-label rapamycin prescribing for longevity purposes remains uncommon but not unheard of, and is available through select private longevity physicians at a cost of roughly £150 to £400 per month, including medical monitoring. The risks, including immunosuppression and potential impact on wound healing, mean this is emphatically not a supplement to acquire without professional oversight.

    For a thorough review of the current evidence on pharmacological longevity interventions, the Lancet has published several accessible analyses in recent years, and remains the most authoritative English-language source for clinically grounded readers.

    The Cost of Longevity in 2026: A Realistic Assessment

    The honest picture of longevity treatments 2026 is one of tiered accessibility. At the most accessible end, CGM programmes and NMN supplementation are available to anyone spending £50 to £100 per month. Mid-tier interventions, supervised senolytic protocols, comprehensive bloodwork panels measuring biological age via DNA methylation testing (available from companies such as Chronomics, based in the UK), and structured rapamycin regimes, sit in the £500 to £3,000 annual range. At the apex, full-service longevity clinics offering everything from hyperbaric oxygen therapy to DEXA body composition scanning charge upwards of £5,000 per year for membership packages.

    What has changed is not that the top tier has become cheaper, but that genuinely evidence-backed interventions now exist at every price point. The longevity treatments 2026 landscape no longer requires you to be Peter Thiel. It does require you to be informed, to engage with real clinical evidence rather than marketing, and to work with qualified medical professionals when prescription-grade interventions are involved. The science has never been more serious. That, at least, is worth something.

    Frequently Asked Questions

    What are the most evidence-backed longevity treatments available in the UK in 2026?

    The treatments with the strongest clinical evidence include continuous glucose monitoring for metabolic health, NAD+ precursor supplements such as NMN and NR, and senolytic protocols combining quercetin with dasatinib. Rapamycin is also gaining attention but requires careful medical supervision due to its immunosuppressant properties.

    How much do longevity treatments cost in the UK?

    Costs vary considerably. CGM programmes such as Zoe start at around £299 for an initial phase, NMN supplements cost roughly £40 to £90 per month, and supervised senolytic protocols at private UK clinics typically range from £800 to £2,500. Full-service longevity clinic memberships can exceed £5,000 per year.

    Are senolytics safe to take without medical supervision?

    Quercetin, a key component of the leading senolytic combination, is available over the counter and is generally considered safe. However, dasatinib is a prescription-only drug regulated by the MHRA and should only be taken under qualified medical supervision, as it carries meaningful side-effect risks.

    What is continuous glucose monitoring and do I need a prescription to use it?

    Continuous glucose monitoring involves wearing a small sensor, usually on the upper arm, that tracks blood sugar levels in real time throughout the day. In the UK, non-diabetic users can access CGM through services such as Zoe without a prescription, though NHS-funded CGM remains primarily reserved for patients with Type 1 diabetes.

    Does the NHS offer any longevity-focused treatments or interventions?

    The NHS does not currently offer longevity treatments as a distinct category. However, it does provide CGM for diabetes management, statins for cardiovascular risk reduction, and screening programmes for certain cancers and conditions associated with ageing. Most of the newer longevity interventions discussed in this article are available only through private clinics.

The Latest